Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 1998

View Archived Issues

SmithKline Beecham: Q2 1998 highlights

Centocor: Q2 1998 highlights

Budesonide is superior to mesalamine in the treatment of Crohn's disease

Clodronate may prevent tumor metastasis in patients with breast cancer

Elan subsidiary obtains patent rights for Cytel's integrin-blocking antibodies

Genome Therapeutics and Cadus join forces in the search for new therapeutic targets

Freezing cancerous tissue may be a therapeutic option for the treatment of liver cancer

Cannabinoid antagonist SR-141716 may be effective in treatment of alcoholism and appetite disorders

Anastrozole, a potent aromatase inhibitor, is effective against postmenopausal endometriosis

Implanon found to be as effective as Norplant but easier to insert and remove

Kotobuki also conducting research on COX-2 inhibitors

Antifungal agents disclosed by Sankyo in patent literature

Kanebo reveals new immunosuppressants in the pipeline

Selective beta3-adrenergic agents reported in development at Tokyo Tanabe

Akzo Nobel claims antipsychotic piperidine derivatives

Medivir synthesizes esters of antiviral nucleosides with improved bioavailability

Novel signal transduction inhibitors reported by Zeneca

TA-270 inhibits the immediate and late asthmatic response and blocks DTH in animal studies

Preclinical studies suggest that Tanabe's ETA antagonist holds promise for treating heart failure

BLP25 cancer vaccine enters phase I testing in patients with NSCLC

Another pharmaceutical merger takes place: Elan acquisition of Neurex finalized

Innogenetics establishes U.S. subsidiary

U.S. patent issued for MediChem Research's antiviral biflavanoids

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026